君實生物(688180.SH)：預計2024年淨虧損12.92億元左右
格隆匯1月17日丨君實生物(688180.SH)公佈，1、經財務部門初步測算，預計2024年年度實現營業收入194,900.00萬元左右，與上年同期相比增長44,645.01萬元左右，同比增長29.71%左右。2、預計2024年年度研發費用為127,400.00萬元左右，與上年同期相比減少66,346.95萬元左右，同比減少34.24%左右。3、預計2024年年度實現歸屬於母公司所有者的淨利潤-129,200.00萬元左右，與上年同期相比虧損減少99,143.19萬元左右，同比虧損減少43.42%左右。4、預計2024年年度實現歸屬於母公司所有者扣除非經常性損益後的淨利潤-127,300.00萬元左右，與上年同期相比虧損減少102,455.88萬元左右，同比虧損減少44.59%左右。
公司2024年年度歸屬於母公司所有者的淨利潤仍出現虧損，但虧損金額與上年同期相比減少，主要系公司積極落實“提質增效重回報”行動方案，持續加強各項費用管控，降低單位生產成本，提升銷售效率，並將資源聚焦於更具潛力的研發項目。報吿期內，預計公司研發費用為127,400.00萬元左右，與上年同期相比減少34.24%左右。公司在控制研發費用的同時維持了核心管線的高效推進，並取得多項進展。報吿期內，特瑞普利單抗用於晚期三陰性乳腺癌一線治療、晚期腎細胞癌一線治療及廣泛期小細胞肺癌一線治療的新適應症上市申請獲得國家藥品監督管理局（以下簡稱“國家藥監局”）批准，一線治療黑色素瘤、聯合貝伐珠單抗一線治療晚期肝細胞癌的新適應症上市申請獲得國家藥監局受理；昂戈瑞西單抗注射液獲得國家藥監局批准上市。公司正加快推進抗腫瘤抗BTLA單抗tifcemalimab（代號：TAB004/JS004）、抗IL-17A單抗（代號：JS005）等後期階段管線的研發和上市申請等工作，並持續探索包括PD-1/VEGF雙特異性抗體（代號：JS207）、Claudin18.2ADC藥物（代號：JS107）、PI3K-α口服小分子抑制劑（代號：JS105）、CD20/CD3雙特異性抗體（代號：JS203）、抗DKK1單克隆抗體（代號：JS015）等產品在內的早期階段管線，儘快推動更多優勢產品和適應症進入註冊臨牀試驗階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
